China Veterinary Medicine Market Size, Share, By Product (Biologics, Pharmaceuticals), By Animal Type (Production Animals, Companion Animals), China Veterinary Medicine Market Insights, Industry Trend, Forecasts to 2035.

China Veterinary Medicine Market Insights Forecasts to 2035

• China Veterinary Medicine Market Size 2024: USD 3.21 Bn
• China Veterinary Medicine Market Size 2035:  USD 7.83 Bn
• China Veterinary Medicine Market CAGR 2024: 8.44%
• China Veterinary Medicine Market Segments: Product and Animal Type

The China veterinary medicine market is a broad sector which is encompassing veterinary pharmaceuticals, vaccines, medicated feed additives, biologics, diagnostics, and related products used for the prevention, diagnosis, treatment, and control of animal diseases. The market is being pushed by the rapid expansion of the livestock industry, rising demand for animal protein, an increase in pet ownership, enhanced animal welfare awareness, and strong government support for the prevention of food safety. With the ongoing legislative reforms, large-scale farming modernization, and the increased investments from both local and global enterprises, China has emerged as one of the world’s largest and the fastest growing veterinary medicine markets.

China’s veterinary medicine clinical trial support providers are increasingly leveraging wearable technology, telemedicine, electronic data capture, and artificial intelligence. These tools enable the real-time monitoring of animal health, remote data collection from farms and veterinary clinics, and continuous disease surveillance, which is expanding the reach of clinical trials across China’s vast geographic regions. Providers are implementing hybrid and decentralized trial designs to encourage greater involvement from both cattle and companion animals. Furthermore, adaptive clinical trial designs are being used to improve dose, treatment regimens, and vaccine efficacy. The application of sophisticated analytics, predictive modelling, and real-world evidence enhances post-market surveillance, increases regulatory compliance with NMPA veterinary standards, and speeds up the entrance of new veterinary pharmaceuticals and biologics into the Chinese market.

Market Dynamics of the China Veterinary Medicine Market

The China veterinary medicine market is driven by the expanding livestock industry, an increase in pet ownership, rising incomes, strong government support for animal health and the food safety, technological advancements, and growing awareness of animal welfare. There is an increase in demand for high-quality veterinary pharmaceuticals, vaccines, biologics, and medicated feed additives, which is fueling both domestic innovation and imports. there is rapid urbanization and a growing wealthy middle class are driving up spending on companion animal care and preventative veterinary services, while the modernization of large-scale farms raises the demand for improved livestock vaccines, diagnostics, and disease prevention solutions. Government measures, such as national disease control programs and vaccination mandates, as well as the delivery of veterinary medicines, are driving overall expansion in the Chinese veterinary medicine industry.

The China veterinary medicine market is restrained by intense domestic competition and price pressures, lengthy and stringent NMPA veterinary regulations, dependence on imported high-end technologies for innovative drugs and biologics, reimbursement challenges for animal health products, geopolitical uncertainties affecting trade, and slow technology transfer from research to commercialization, requiring foreign firms to adopt localized strategies.

The future of the China veterinary medicine market is bright and promising, which is driven by the new opportunities from digital health integration, real-world evidence generation, AI-assisted animal health monitoring, and the hybrid or decentralized clinical trials for livestock and companion animals. Predictive analytics, linked wearables, smart sensors, and electronic data collection systems are being used to improve animal health monitoring, maximize trial efficiency, increase disease surveillance, and ensure regulatory compliance with NMPA veterinarian standards. These technologies are accelerating vaccine and biologics development, post-market monitoring, and rapid market access for innovative veterinary medicines.

Market Segmentation

The China Veterinary Medicine Market share is classified into product and animal type.

By Product

The China veterinary medicine market is divided by product into biologics, pharmaceuticals. Among these, the pharmaceuticals segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is because pharmaceuticals are widely used for both preventive and curative treatments in large-scale animal farming operations.

By Animal Type

The China veterinary medicine market is divided by animal type into production animals, companion animals. Among these, the production animals segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. This is because the rising consumption of meat and dairy products due to a growing middle class and changing dietary habits drives the need for enhanced animal health management to ensure food safety and quality.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the China veterinary medicine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in China Veterinary Medicine Market

• Hangzhou Richerpharm Technology Co., Ltd.
• Zhejiang Kangdi
• Hisoar Pharmaceutical
• Qilu Animal Health
• Ningxia Tairui
• Jiangsu Hualing
• Inner Mongolia Veyong
• Hubei Hongyuan
• Others

Recent Developments in China Veterinary Medicine Market

In April 2024, Boehringer Ingelheim partnered with Sino Biopharmaceutical to collaborate on developing innovative products for human and animal health in China, strengthening its presence and relevance in the China veterinary medicine market.

In May 2023, Kuehne+Nagel partnered with Elanco Animal Health to establish a new manufacturing warehouse and distribution center in China, strengthening Elanco’s supply chain infrastructure and supporting growth in the China veterinary medicine market.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the China, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the China veterinary medicine market based on the below-mentioned segments:

China Veterinary Medicine Market, By Product

• Biologics
• Pharmaceuticals

China Veterinary Medicine Market, By Animal Type

• Production Animals
• Companion Animals.